产品
编 号：F620450
分子式：C48H48F2N10O5
分子量：882.96
分子式：C48H48F2N10O5
分子量：882.96
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 2212020-52-3
产品详情
生物活性：
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete.
体内研究：
Orforglipron (血浆浓度达到 0.94-4.8 nM in plasma concentration，静脉注射 30 反正；或 0.05-0.1 mg/mL，灌胃，5天) 在食蟹猴动物模型中以剂量依赖的方式抑制食蟹猴的食物摄取，促进胰岛素分泌并降低血糖。Orforglipron (0.05-1.35 mg/kg，灌胃) 在给药 2 小时后达到最大血浆浓度 Cmax，血浆药物暴露增加与剂量增加大致呈正比，表明 Orforglipron 在胃肠道中呈剂量依赖性的被吸收。Orforglipron 在食蟹猴体内的药代动力学分析routeDose (mg/kg)Tmax (h)Cmax (ng/mL)AUC0-24h (ng·h/mL)
i.g.0.052.04.7823.7
i.g.0.152.020.7135
i.g.0.452.032.0208
i.g.1.352.01481040
Animal Model:cynomolgus monkey model
Dosage:0.9-4.8 nM; 0.05-0.1 mg/mL
Administration:continuous i.v. administration for 30 minutes until a plasma concentration of 0.9-4.8 nM at steady state;i.g. for 5 days with dose of 0.05-0.1 mg/mL
Result:Increased insulin secretion and decreased plasma-glucose.Suppressed food intake in a dose-dependent manner.
体外研究：
Orforglipron is an incretin secreted from L cells of the small intestine when nutrients pass through the digestive tract, and glucose is transmitted via the GLP-1 receptor. Orforglipron exhibits various actions such as dependent gastric emptying delay, and feeding suppression.
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete.
体内研究：
Orforglipron (血浆浓度达到 0.94-4.8 nM in plasma concentration，静脉注射 30 反正；或 0.05-0.1 mg/mL，灌胃，5天) 在食蟹猴动物模型中以剂量依赖的方式抑制食蟹猴的食物摄取，促进胰岛素分泌并降低血糖。Orforglipron (0.05-1.35 mg/kg，灌胃) 在给药 2 小时后达到最大血浆浓度 Cmax，血浆药物暴露增加与剂量增加大致呈正比，表明 Orforglipron 在胃肠道中呈剂量依赖性的被吸收。Orforglipron 在食蟹猴体内的药代动力学分析routeDose (mg/kg)Tmax (h)Cmax (ng/mL)AUC0-24h (ng·h/mL)
i.g.0.052.04.7823.7
i.g.0.152.020.7135
i.g.0.452.032.0208
i.g.1.352.01481040
Animal Model:cynomolgus monkey model
Dosage:0.9-4.8 nM; 0.05-0.1 mg/mL
Administration:continuous i.v. administration for 30 minutes until a plasma concentration of 0.9-4.8 nM at steady state;i.g. for 5 days with dose of 0.05-0.1 mg/mL
Result:Increased insulin secretion and decreased plasma-glucose.Suppressed food intake in a dose-dependent manner.
体外研究：
Orforglipron is an incretin secreted from L cells of the small intestine when nutrients pass through the digestive tract, and glucose is transmitted via the GLP-1 receptor. Orforglipron exhibits various actions such as dependent gastric emptying delay, and feeding suppression.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备